Axonics Modulation Technologies logo
Axonics Modulation Technologies AXNX
report update icon

Quarterly report 2024-Q3
added 05-16-2026

Axonics Modulation Technologies Income Statement 2023-2011 | AXNX

Brief overview of financial performance at Axonics Modulation Technologies

The figures are compared over a five-year interval. Axonics Modulation Technologies reported revenue of 707 thousand dollars in 2018 and 366 million dollars by 2023. The total change was +51721.6%, with a CAGR of approximately 249.1%. Revenue growth reflects a pronounced phase of business expansion.

At the gross-profit level, the result moved from $351 thousand to $275 million, a change of +78120.5%. The relationship between sales and direct costs improved over the period. At the margin level, the figure shifted from 49.6% to 74.9%. The expansion indicates stronger pricing power or better control of direct costs.

The five-year EBITDA result moved by +56.5%: from −31.2 million dollars to −13.6 million dollars. Operating performance weakened relative to revenue. Comparing the endpoints gives EBITDA margins of −4411.7% and −3.7%. The business generated more EBITDA from each unit of revenue.

The net financial result changed from −$32.5 million to −$6.1 million. The loss reduction is constructive, but the recovery is incomplete.

Financial takeaway

Positive developments coexist with areas of weakness. The financial profile benefits from a stronger final result, higher operating efficiency and sales growth. Caution is warranted because of a narrow EBITDA buffer. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Axonics Modulation Technologies

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 2.82 B 2.41 B 1.85 B 792 M 106 M - - - - - - -

Shares

49.1 M 46.7 M 43.1 M 37 M 28.6 M 7 M 2.56 M - - - - - -

Historical Prices

- 60.5 56 49.9 27.7 15.1 - - - - - - -

Net Income

-6.09 M -59.7 M -80.1 M -54.9 M -79.9 M -32.5 M -18.1 M -17.4 M - - - - -

Revenue

366 M 274 M 180 M 112 M 13.8 M 707 K 128 K - - - - - -

Cost of Revenue

91.8 M 76 M 64.6 M 44.4 M 6.49 M 356 K 118 K - - - - - -

Gross Profit

275 M 198 M 116 M 67.1 M 7.33 M 351 K 10 K - - - - - -

Operating Income

-26.1 M -64.9 M -71.8 M -53.8 M -80.6 M -32.1 M -18.2 M - - - - - -

Interest Expense

624 K -2.43 M -7.43 M -1.87 M -2.31 M -1.34 M -22 K - - - - - -

EBITDA

-13.6 M -53.2 M -62.7 M -52 M -79.4 M -31.2 M -17.4 M -16.8 M - - - - -

Operating Expenses

301 M 263 M 188 M 121 M 87.9 M 32.5 M 18.2 M - - - - - -

General and Administrative Expenses

45.8 M 40.2 M 30 M 25.6 M 19.1 M 9.36 M 4.82 M 4.46 M - - - - -

All numbers in USD currency

Quarterly Income Statement Axonics Modulation Technologies

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

51.1 M 50 M 50.9 M 50.8 M 49.2 M 49.1 M 48.6 M 49.5 M 47.2 M 45.3 M 45.1 M 46.3 M 44.8 M 42.8 M 39.6 M 39.9 M 38.8 M 36.4 M 33.6 M 34.1 M 28.1 M 27.9 M 27.8 M 27.8 M 2.83 M 2.82 M 2.8 M 2.78 M 2.71 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-21 K 6.9 M -19.1 M - 3.93 M -7.34 M -9.25 M - -16.3 M -21.4 M -22.7 M - -17.2 M -25.1 M -22.5 M - -9.17 M -19.8 M -14.6 M - -25 M -19.1 M -13.1 M - -7.57 M -8.65 M -6.6 M - -4.52 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

116 M 115 M 91.4 M - 93.1 M 92.9 M 70.6 M - 70.4 M 69 M 48.4 M - 46.9 M 45.9 M 34.4 M - 35.2 M 15.2 M 26.3 M - 1.31 M 1.49 M 1.08 M - 201 K 12 K - - 128 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

26.5 M 25.4 M 22.2 M - 24 M 22.7 M 18.2 M - 19.1 M 18.8 M 15.2 M - 15.7 M 17.1 M 14 M - 13.4 M 8.46 M 9.9 M - 632 K 772 K 548 K - 106 K 5 K - - 118 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

89.7 M 89.1 M 69.3 M - 69.1 M 70.2 M 52.5 M - 51.3 M 50.2 M 33.2 M - 31.2 M 28.7 M 20.4 M - 21.8 M 6.75 M 16.4 M - 677 K 716 K 529 K - 95 K 7 K - - 10 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-6.27 M 3.68 M -19.2 M - -687 K -12.1 M -14.4 M - -16.4 M -21.4 M -23.5 M - -16.5 M -16 M -21.6 M - -8.77 M -19.4 M -14.7 M - -25 M -19.3 M -13.6 M - -7.54 M -8.62 M -6.53 M - -4.59 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

8 K -32 K -59 K - -83 K 174 K 683 K - -1.9 M -839 K -289 K - -229 K -5.85 M -1.45 M - -434 K -443 K -552 K - -586 K -629 K -532 K - -196 K -234 K -149 K - -8 K - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

3.03 M 9.76 M -16 M - 8.61 M -6.03 M -11.6 M - -7.53 M -15.5 M -20.5 M - -10 M -12.2 M -20.5 M - -7.52 M -18.6 M -14.3 M - -24.2 M -18.7 M -13.3 M - -6.88 M -8.19 M -6.31 M - -4.08 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

95.9 M 85.5 M 88.4 M - 69.8 M 82.3 M 66.9 M - 67.6 M 71.6 M 56.8 M - 47.7 M 44.7 M 42 M - 30.6 M 26.2 M 31.1 M - 25.7 M 20 M 14.1 M - 7.64 M 8.62 M 6.53 M - 4.6 M - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

23.8 M 16.3 M 15.1 M - 11.8 M 10.7 M 12.2 M - 9.39 M 10.6 M 10 M - 8.72 M 8.04 M 6.63 M - 5.77 M 5.54 M 7.65 M - 5.16 M 4.36 M 4.02 M - 2.79 M 1.64 M 1.44 M - 1.1 M - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Axonics Modulation Technologies (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
AxoGen AxoGen
AXGN
$ 48.73 1.42 % $ 2.24 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 18.34 0.55 % $ 1.41 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 3.87 % $ 14.6 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 82.22 0.02 % $ 4.48 B britainBritain
LENSAR LENSAR
LNSR
$ 8.2 0.24 % $ 98.1 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.27 1.67 % $ 631 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.34 0.1 % $ 434 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.4 10.38 % $ 24.9 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inogen Inogen
INGN
$ 5.75 0.17 % $ 153 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Butterfly Network Butterfly Network
BFLY
$ 8.84 0.79 % $ 2.18 B usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA